Company news

Innovent Biologics, Inc. news in 2026

Innovent Biologics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Voluntary announcement - innovent's partner ollin biosciences and its next-generation medicines for patients with vision-threatening eye diseases to be acquired

November 16, 2026

Voluntary announcement - Zybrivo (sintilimab) receives positive CHMP opinion for first-line treatment of non-squamous non-small cell lung cancer

November 15, 2026

Voluntary announcement - inclusion of seven innovative products including mazdutide and PECONDLE in the 2026 national reimbursement drug list

November 15, 2026

Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List

November 13, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 5, 2026

Inside information announcement - product revenue in the third quarter of 2026

October 28, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

2026 Interim report

September 29, 2026

Voluntary announcement - Jaypirca (pirtobrutinib) approved in China for a new indication in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across all lines of therapy

September 28, 2026

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

September 27, 2026

Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market

September 22, 2026

Innovent Announces 2026 Interim Results and Business Updates

August 25, 2026

Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China

August 9, 2026

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

July 14, 2026

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

June 30, 2026

Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma

June 21, 2026

World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA

June 4, 2026

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

May 31, 2026

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

May 31, 2026

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026

2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

May 21, 2026

Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer

May 10, 2026

Innovent to Present New Clinical Data of IBI363(PD-1/IL-2α-biased bispecific fusion protein) at the 2026 ASCO Annual Meeting

April 21, 2026

Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases

April 9, 2026

Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License

April 8, 2026

Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

March 30, 2026

Innovent Announces 2025 Annual Results and Business Updates

March 26, 2026

The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China

March 23, 2026

Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study

March 22, 2026

Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

March 1, 2026

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

February 12, 2026

Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology

February 8, 2026

Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma

January 26, 2026

Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration

January 8, 2026

Decks in 2026